Possible Role of Apoptosis in the Pathogenesis of Bleomycin-Induced Scleroderma

Journal of Investigative Dermatology

Volumn 122, Issue 1, 2004, Pages 44-50

  Yamamoto, Toshiyuki ^a   Nishioka, Kiyoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bleomycin; Caspase 3; Fas; Fas ligand; Mouse model; Scleroderma

Indexed keywords

BLEOMYCIN; CASPASE 3; DNA FRAGMENT; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA GEL BLOT ANALYSIS; DRUG INJECTION VOLUME; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEMALE; GEL ELECTROPHORESIS; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; MONONUCLEAR CELL; MOUSE; MOUSE STRAIN; NICK END LABELING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS; UPREGULATION;

EID: 1642575264     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-202X.2003.22121.x     Document Type: Article

References (36)

1. Arora PD, McCulloch CA: The deletion of transforming growth factor-beta induced myofibroblasts depends on growth conditions and actin organization. Am J Pathol 155:2087-2099, 1999
2. Bonfoco E, Stuart PM, Brunner T, et al: Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 9:711-720, 1998
3. Fadeel B, Orrenius S, Zhivotovsky B: Apoptosis in human disease. A new skin for the old ceremony? Biochem Biophys Res Commun 266:699-717, 1999
4. Griffith TS, Ferguson TA: The role of FasL-induced apoptosis in immune privilege. Immunol Today 18:240-244, 1997
5. Grodzicky T, Elkon KB: Apoptosis in rheumatic diseases. Am J Med 108:73-82, 2000
6. Hamilton RF Jr, Li L, Felder TB, Holian A: Bleomycin induces apoptosis in human alveolar macrophages. Am J Physiol 269:L318-L325, 1995
7. Hohlbaum AH, Moe S, Marshak-Rothstein A: Opposing effects of transmembrane and soluble Fas-ligand on inflammation and tumor cell survival. J Exp Med 191:1209-1219, 2000
8. Itoh N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243, 1991
9. Jelaska A, Korn JH: Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43:2230-2239, 2000
10. Krieg T, Meurer M: Systemic scleroderma. Clinical and pathophysiological aspects. J Am Acad Dermatol 18:457-481, 1988
11. Kuwano K, Hagimoto N, Kawasaki M, et al: Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 104:13-19, 1999
12. LeRoy EC, Trojanowska M, Smith EA: The pathogenesis of scleroderma (systemic sclerosis, SSc). Clin Exp Rheumatol 9:173-177, 1991
13. Los M, van de Crean M, Penning LC, et al: Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 375:81-83, 1995
14. Nagata S: Fas ligand and immune evasion. Nat Med 2:1306-1307, 1996
15. Nagata S, Golstein P: The Fas death receptor. Science 267:1449-1456, 1995
16. Omar T, Geraldine P, Belehradek J Jr, Mir LM: Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 53:5462-5469, 1993
17. Ortiz A, Lorz C, Gonzalez-Cuadrado S, Moral RGD, O'Valle F, Egido J: Cytokines and Fas regulate apoptosis in murine renal interstitial fibroblasts. J Am Soc Nephrol 8:1845-1854, 1997
18. Ortiz LA, Moroz K, Liu J-Y, et al: Alveolar macrophage apoptosis and TNF-α, but not p53, expression correlate with murine response to bleomycin. Am J Physiol 275:1208-L1218, 1998
19. Restifo NP: Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6:493-495, 2000
20. Ricci-Vitiani L, Conticello C, Zeuner A, De Maria R: CD95/CD95L interactions and their role in autoimmunity. Apoptosis 5:419-424, 2000
21. Saitoh A, Kawanabe T, Weidong H, et al: Selective upregulation of fibroblast Fas ligand expression, and prolongation of Fas/Fas ligand-mediated skin allograft survival, by retinoic acid: The skin as a retinoid-inducible immune privilege site. J Invest Dermatol 115:154-156, 2000
22. Santiago B, Galindo M, Rivero M, Pablos JL: Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 44:1667-1676, 2001
23. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G: Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785-792, 1996
24. Sgonc R, Dietrich H, Sieberer C, Wick G, Christner PJ, Jimenez SA: Lack of endothelial cell apoptosis in the dermis of tight skin 1 and tight skin 2 mice. Arthritis Rheum 42:581-584, 1999
25. Siegel RM, Fleisher TA: The role of Fas and related death receptors in autoimmune and other disease states. J Allergy Clin Immunol 103:729-738, 1999
26. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178, 1993
27. Thornberry NA, Rano TA, Peterson EP, et al: A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 272:17907-17911, 1997
28. Vaishnaw AK, McNally JD, Elkon KB: Apoptosis in the rheumatic diseases. Arthritis Rheum 40:1917-1927, 1997
29. Walczak H, Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58-66, 2000
30. Yamamoto T, Nishioka K: Animal model of sclerotic skin. IV. Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 117:999-1001, 2001
31. Yamamoto T, Nishioka K: Animal model of sclerotic skin. V. Increased expression of α-smooth muscle actin in flbroblastic cells in bleomycin-induced scleroderma. Clin Immunol 102:77-83, 2002
32. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112:456-462, 1999a
33. Yamamoto T, Takahashi Y, Takagawa S, Katayama I, Nishioka K: Animal model of sclerotic skin. II. Bleomycin-induced scleroderma in genetically mast cell deficient WBB6F1-W/Wv mice. J Rheumatol 26:2628-2634, 1999b
34. Yamamoto T, Takagawa S, Katayama I, Nishioka K: Anti-sclerotic effect of transforming growth factor-β antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 92:6-13, 1999c
35. Yamamoto T, Kuroda M, Takagawa S, Nishioka K: Animal model of sclerotic skin. III. Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 292:535-541, 2000
36. Zhang HY, Phan SH: Inhibition of myofibroblast apoptosis by transforming growth factor beta 1. Am J Respir Cell Moll Biol 21:658-665, 1999